Efficacy of canakinumab in mild or severe COVID-19 pneumonia

Falasca Katia¹ | Di Penta Myriam² | Claudio Ucciferri¹,³ |
Antonio Auricchio¹ | Marta Di Nicola⁴ | Michele Marchioni⁴ |
Celletti Eleonora² | Sabatini Emanuela² | Francesco Cipollone² |
Jacopo Vecchiet¹

¹Department of Medicine and Science of Aging, Clinic of Infectious Diseases, University “G. D’Annunzio” Chieti-Pescara, Chieti, Italy
²Department of Medicine and Aging Sciences, Internal Medicine, “G. D’Annunzio” University, Chieti, Italy
³Department of Medicine and Health Sciences, University of Molise, Campobasso, Italy
⁴Department of Medical, Oral and Biotechnological Sciences, Laboratory of Biostatistics, G. d’Annunzio University of Chieti, Chieti, Italy

Correspondence
Falasca Katia, Clinic of Infectious Diseases, Dept. of Medicine and Science of Aging, University “G. D’Annunzio” School of Medicine, Via dei Vestini, 66100 Chieti, Italy.
Email: k.falasca@unich.it

Abstract

Background: Clinicians all around the world are currently experiencing a pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Several therapeutic strategies have been used until now but, to date, there is no specific therapy to treat SARS-CoV-2 infection. In this study, we used canakinumab, a human monoclonal antibody targeting interleukin-1 beta to improve respiratory function and laboratory parameters compared with standard therapy (hydroxychloroquine plus lopinavir/ritonavir).

Methods: We enrolled 34 patients with mild or severe non intensive care unit (ICU) coronavirus disease 2019 (COVID-19): 17 patients treated with standard therapy and 17 patients treated with a subcutaneous single dose of canakinumab 300 mg. We collected data about oxygen supports and laboratory parameters such as inflammation indices and hemogasanalysis. We compared the data collected before the administration of canakinumab (T0), 3 days after T0 (T1) and 7 days after T0 (T2) with the same data from patients taking the standard therapy.

Results: We observed a reduction in inflammation indices and a significant and rapid increase in P/F ratio in canakinumab group, with improvement of 60.3% after the administration. We reported a significant reduction in oxygen flow in patients treated with canakinumab (−28.6% at T1 vs. T0 and −40.0% at T2 vs. T1). Conversely, the standard group increased the supply of high oxygen at T1 versus T0 (+66.7%), but reduced oxygen flows at T2 versus T1 (−40.0%).

Conclusion: In hospitalized adult patients with mild or severe non ICU COVID-19, canakinumab could be a valid therapeutic option. Canakinumab therapy causes rapid and long-lasting improvement in oxygenation levels in the absence of any severe adverse events.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2020 The Authors. Immunity, Inflammation and Disease published by John Wiley & Sons Ltd.
INTRODUCTION

A new challenge has recently emerged for the healthcare community across the world: the infection caused by a novel coronavirus, officially known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), responsible of a clinical condition called coronavirus disease 2019 (COVID-19). The clinical presentation of this pathology includes fever, dry cough, fatigue, and acute respiratory distress syndrome that can lead infected patients to death. High infectivity, ability to be transmitted even during asymptomatic phase and relatively low virulence have resulted in a rapid transmission of this virus beyond geographic regions, leading to a pandemic.

Since the appearance of the first cases, within a short span of just over 3 months, the infection has spread more than 200 countries across the world.

To confine this potentially deadly virus, many countries all over the world and World Health Organization have strategized to interrupt the human to human contacts, isolate patients at early stages, accelerate research, and communicate correct information to the public trying to minimize the social and economic impact. There is currently a deep gap about the knowledge of the mechanisms underlying the pathogenic processes of the virus to develop specific drugs to reduce the mortality linked to the infection.

Various drugs are quickly being developed and new targets are being identified every day, and also numerous drugs are undergoing clinical trials. Interesting and discordant research have been published to provide the best protection of the global community before a vaccine can be made available.

Coronaviruses use their S protein to enter host cells. In humans, SARS-2 entry happen via the host enzyme angiotensin-converting enzyme 2 (ACE2) receptor that is located on the cell's surface. The downregulation of ACE2 usually leads to an overproduction of angiotensin II. Angiotensin II in turn activates its Ra type receptor, and this increases the permeability of lung vessels. Therefore, the initial and the most serious prolonged injury occurs to the lungs. The immune response has a pivot role for the resolution of SARS infection, but it can also enhance, if not drive, the pathogenesis in the second phase of the disease that is characterized by an upregulation of proinflammatory cytokines and chemokines determining a cytokininc storm in which the interleukines-1β (IL-1β), 1RA, 7, 8, 9, 10, basic FGF2, granulocyte colony stimulating factor (GCSF), granulocyte-macrophage–colony stimulating factor (GM–CSF), interferon-γ, IP10, monocyte chemotactrant protein-1 (MCP1), macrophage inflammatory protein 1α (MIP1α), MIP1β, platelet-derived growth factor B, tumor necrosis factor-α (TNF-α), and vascular endothelial growth factor A are overproduced; some of these, like IL2, IL7, IL10, GCSF, IP10, MCP1, MIP1α, and TNF-α could promote, or mark, disease severity. Another study shows that CD4 T cells of intensive care unit (ICU) patients with COVID-19 produced more IL-6 and GM-CSF than those not requiring ICU, although the numbers, powers, and treatments were not reported. The cytokine storms mediated by overproduction of proinflammatory cytokines have been observed in population with COVID-19.

Several studies are trying to discover a way to block the inflammatory process that generates the damage by using different strategies. For this reason the use of canakinumab, that is an anti-IL-1β human monoclonal antibody, can be considered a valid therapeutic tool for individuals with COVID-19.

We describe a first experience of hospitalized mild or severe non ICU COVID-19 infected patients treated with canakinumab and compared with patients treated with a standard therapy (hydroxychloroquine and protease inhibitors).

MATERIALS AND METHODS

Design of the study

This is a single center cohort study, conducted enrolling patients admitted from March to April 2020 at the Infectious Diseases Clinic and the Internal Medicine Unit, University “G. D’Annunzio,” SS Annunziata Hospital of Chieti, Italy, with diagnosis of COVID-19 pneumonia by real-time PCR on oropharyngeal and nasopharyngeal swabs. Medical records related to the recovery were consulted for each patient, and data regarding anamnesis, laboratory and therapy were collected and tabulated.

Patient selection

All COVID-19 patients were treated (previously or simultaneously) with standard therapy: hydroxychloroquine and protease inhibitors (lopinavir/ritonavir). All patients
needed oxygen supplementation without intubation. We enrolled the first 17 patients who experienced a worsening in P/F ratio value before starting therapy with canakinumab. P/F ratio is a widely used tool to identify acute hypoxemic respiratory failure and it equals the arterial oxygen partial pressure (PaO₂ in mmHg) from the arterial blood gas (ABG) divided by fractional inspired oxygen (FiO₂). All the patients received the approval for the free use of canakinumab by Novartis International AG. After getting permission from Novartis International AG we started the treatment with canakinumab consisting in a single subcutaneous administration of 300 mg. Supportive therapy was to be provided at the discretion of the clinicians. No simple-size calculations were performed.

The standard group was made up of the first 17 patients with confirmed SARS-CoV-2 infection with COVID-19 who had an oxygen saturation of 94% or less while they were breathing ambient air (FiO₂ 21%) or who were starting having a worsening of respiratory function. The patients of the standard group did not receive any other therapy than hydroxychloroquine plus lopinavir or ritonavir to be enrolled as standard group.

### 2.3 Study assessment

Clinicians collected demographic and clinical data about the patients enrolled. Laboratory values were collected at the time of enrollment and, in the canakinumab group, before the administration of canakinumab (time 0, T0, or enrollment time), three days after enrollment (time 1, T1) and seven days after enrollment (time 2, T2). We collected data about serum creatinine, blood coagulation panel including prothrombin time, activated partial thromboplastin time ratio, fibrinogen and D-dimer, lactate dehydrogenase (LDH), C-reactive protein (CRP), blood urea nitrogen, troponine I, alanine aminotransferase, aspartate aminotransferase, gamma-glutamyl transferase, alkaline phosphatase, total and fractionated bilirubin, lipase, amylase, and blood glucose levels.

Data on patients’ oxygen support requirements at the three times were collected (other controls were performed at the clinician’s discretion): analysis of arterial blood gases and electrolytes including P/F ratio. All the enrolled patients were studied using chest RX and/or computed tomography.

The standard group was made up of 17 patients with confirmed SARS-CoV-2 infection who had an oxygen saturation of 94% or less while they were breathing ambient air (FiO₂ 21%) and who were starting having a worsening of respiratory function in standard therapy with lopinavir or ritonavir 200/50 mg 2 cps/bid and hydroxychloroquine 200 mg/bid.

The study protocol was performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki. The patients have signed an information consent for use off-label the drugs.

### 2.3.1 Statistical analysis

No sample-size calculations were performed. Quantitative variables were reported as median and interquartile range (IQR) while quantitative data were summarized as frequency and percentage. Outcomes of interest were analyzed using different linear mixed models. This approach allows explicit modeling of the within-person and between-person variation in the outcome, while taking into account the correlation between repeated measurements on the same individual. Linear mixed model for repeated measurements was used to regress T0, T1, and T2 measures on the fixed-effect factors assuming unstructured covariance matrix. The p-value were not adjusted for multiple comparisons. All the statistical analyses were performed using R software environment for statistical computing and graphics version 3.5.2 (R Foundation for Statistical Computing, Vienna, Austria. https://www.R-project.org/).

### 3 RESULTS

#### 3.1 Characteristics of sample population study

Of the 34 patients enrolled with COVID-19, 17 were male (50%), and all of them were of Caucasian ethnicity with a median age of 55.5 (IQR: 48.3–66.5) years (Table 1). No differences between the two groups were evidenced about symptoms and initial clinical conditions.

#### 3.2 Ematochemical values

With regard to the blood chemistry parameters, the patients showed a significant improvement in the number of lymphocytes ($p = .005$) and platelets ($p < .001$) over time. Also D-dimer and fibrinogen decreased significantly, with a significant reduction over time ($p = .034$ and $p = .029$, respectively). Inflammatory indices, such as CRP, have significantly normalized over time ($p = .001$), as well as LDH ($p = .003$) (Table 2). Also the lactate reduced in standard group (T0 1.4 [1.0–1.8]; T1 1.5 [1.2–2.0]; T2 1.9 [1.5–2.0]) and significantly in canakinumab group (T0 2.3
TABLE 1 Baseline clinical characteristics of patients, data are expressed as median and Interquartile range (IQR)

|                      | Canakinumab group | Standard group | p Value |
|----------------------|-------------------|----------------|---------|
| Gender               |                   |                |         |
| Female               | 2 (11.8%)         | 4 (23.5%)      | .368    |
| Male                 | 15 (88.2%)        | 13 (76.5%)     |         |
| Age (year)           | 53.0 (48.0, 62.0) | 59.0 (50.0, 72.0) | .255    |
| Clinical features at baseline |       |                |         |
| Fever                | 16 (94.1%)        | 15 (88.2%)     | .545    |
| Cough                | 14 (82.4%)        | 12 (70.6%)     | .419    |
| Dyspnea              | 8 (47.1%)         | 14 (82.4%)     | .031    |
| Asthenia             | 6 (35.3%)         | 3 (17.6%)      | .244    |
| Nausea               | 5 (29.4%)         | 2 (11.8%)      | .203    |
| Headache/dizziness   | 2 (11.8%)         | 2 (11.8%)      | .998    |
| Diastolic blood pressure (mmHg) | 70.0 (60.0, 80.0) | 80.0 (70.0, 80.0) | .042    |
| Systolic blood pressure (mmHg) | 120.0 (120.0, 130.0) | 130.0 (120.0, 140.0) | .062    |
| Heart rate/min       | 90.0 (85.0, 99.0) | 84.0 (80.0, 90.0) | .094    |
| Respiratory rate/min | 20.0 (18.0, 20.0) | 20.0 (18.0, 26.0) | .411    |

Note: p < .05 are in bold.
*Pearson’s χ² test.
*Mann–Whitney U test.

[1.2–6.0]; T1 1.9 [1.0–6.0]; T2 1.6 [1.0–2.6]) (Figure 1). We have noticed an increase in liver function and renal indices but always within normal ranges (Table 2).

3.3 | Respiratory parameters

The detailed analysis of ABG showed a faster increase of the pulmonary functions in canakinumab group in comparison to the standard group. In particular, the canakinumab group had a P/F ratio value of 174 (IQR: 138–252) at T0, a P/F ratio value of 280 (IQR: 160–345) at T1 and a P/F ratio value of 306 (IQR: 235–404) at T2. We observed a significant and rapid increase in P/F ratio in patients treated with canakinumab, in fact the canakinumab group had an improvement of the P/F ratio in 60.3% while in the standard group in 39.2% (Figure 2). At the baseline the 82.3% of canakinumab patients had an oxygen supplementation with Venturi mask at 6 L/min or more. Conversely, the 52.9% of patients in the standard group were taking an oxygen supplementation with Venturi mask at 6 L/min or more. The canakinumab group significantly reduced the supply of high oxygen flows (−28.6% at T1 vs. T0 and −40.0% at T2 vs. T1). Conversely, in the standard group increased the supply of high oxygen at T1 versus T0 (+66.7%), but reduced the supply of oxygen at T2 versus T1 (−40.0%).

Furthermore, there were no significative differences between the two groups for imaging CT or X-ray chest at the baseline, in fact 13 patients in the canakinumab group and 14 in the standard group showed bilateral typical finding as patchy ground glass opacities.

3.4 | Outcome e adverse events

There were no adverse events into the two groups, except for a slight increase in liver indices in the canakinumab group. No patient belonging to the two groups died. No difference in the outcome between two groups at 40 days was observed: fifteen patients were discharged without oxygen therapy in canakinumab group, while two patients of was discharged requiring oxygen therapy in standard group. Furthermore, there were no other significative differences between the two groups. No sepsis or other adverse events were detected 14 days after administration of canakinumab.

4 | DISCUSSION

In our cohort study, canakinumab showed a significant clinical improvement of respiratory failure compared to standard therapy with hydroxychloroquine and lopinavir or ritonavir in patients infected with SARS-CoV-2 and mild or severe pneumonia.

Canakinumab is a human monoclonal antibody with a specific reactivity only for IL-1 beta with no cross
TABLE 2  Clinical characteristics of patients between standard group and canakinumab group at three times (T0, T1, and T2)

| Variable                      | Baseline (T0) | Third day (T1) | Seventh day (T2) | p Value |
|-------------------------------|---------------|----------------|------------------|---------|
|                               | Standard group | Canakinumab group | Standard group | Canakinumab group | Standard group | Canakinumab group | Group<sup>a</sup> | Time<sup>b</sup> | Interaction<sup>c</sup> |
| Hb (g/dl)                     | 13.4 (13.0, 14.2) | 14.6 (13.0, 15.5) | 13.0 (12.2, 13.5) | 13.3 (11.4, 13.4) | 13.5 (12.2, 14.3) | .710 | .004 | .615 |
| WBC (cells/mcl)               | 7.8 (4.7, 9.0) | 6.3 (4.8, 10.0) | 6.4 (4.5, 7.7) | 7.5 (5.3, 8.5) | 6.4 (5.6, 8.0) | .286 | .730 | .469 |
| Neutrophils (cells/mcl)       | 5.8 (3.1, 7.6) | 5.3 (3.7, 9.0) | 4.8 (2.8, 6.0) | 5.2 (4.0, 6.2) | 4.5 (3.1, 5.6) | .127 | .230 | .173 |
| Lymphocytes (cells/mcl)       | 1.1 (0.8, 1.2) | 0.7 (0.6, 0.9) | 1.1 (0.9, 1.3) | 1.1 (0.8, 1.9) | 1.4 (1.1, 1.7) | 1.4 (1.2, 2.0) | .146 | .005 | .074 |
| PLT (x 10<sup>3</sup> cells/mcl) | 213.0 (151.0, 245.0) | 194.0 (174.0, 226.0) | 243.0 (192.0, 326.0) | 265.0 (224.0, 347.0) | 299.0 (258.0, 386.0) | 244.0 (208.0, 289.0) | .708 | <.001 | .065 |
| Fibrinogen (mg/dl)            | 542.0 (479.0, 622.0) | 639.0 (550.0, 700.0) | 500.0 (450.0, 551.0) | 450.0 (321.0, 530.0) | 400.0 (308.5, 514.0) | 360.0 (329.0, 400.0) | .869 | .029 | .166 |
| d-dimer (ng/ml)               | 0.7 (0.6, 0.9) | 0.8 (0.6, 1.4) | 1.0 (0.9, 1.5) | 0.9 (0.6, 1.1) | 1.0 (0.8, 2.4) | 0.5 (0.4, 0.8) | .659 | .034 | .003 |
| Creatinin (mg/dl)             | 0.8 (0.7, 1.0) | 0.9 (0.8, 1.1) | 0.8 (0.7, 0.8) | 0.9 (0.7, 1.0) | 0.8 (0.6, 0.8) | 0.8 (0.7, 0.8) | .110 | .412 | .241 |
| Blood Urea (mg/dl)            | 35.0 (29.0, 37.0) | 32.0 (24.0, 42.0) | 33.0 (25.0, 38.0) | 27.0 (23.0, 38.0) | 28.0 (25.0, 37.0) | 29.0 (23.0, 34.0) | .308 | .393 | .356 |
| CRP (mg/dl)                   | 136.3 (69.8, 197.0) | 181.0 (125.3, 201.8) | 140.0 (50.8, 194.7) | 17.1 (2.8, 78.0) | 38.0 (16.5, 76.4) | 4.2 (1.5, 5.9) | .545 | .001 | .507 |
| PCT (ng/ml)                   | 0.1 (0.0, 0.2) | 0.2 (0.1, 1.0) | 0.0 (0.0, 0.1) | 0.1 (0.0, 0.2) | 0.0 (0.0, 0.0) | 0.0 (0.0, 0.0) | .014 | .862 | .067 |
| LDH (U/L)                     | 300.0 (291.8, 334.0) | 287.0 (245.0, 374.0) | 410.0 (254.0, 490.0) | 279.0 (221.0, 313.0) | 226.0 (187.5, 267.0) | 199.0 (184.0, 250.0) | .233 | .003 | .745 |
| AST (U/L)                     | 40.0 (28.0, 52.0) | 29.0 (24.0, 37.0) | 48.0 (23.2, 55.0) | 50.0 (30.0, 109.0) | 61.0 (28.5, 85.5) | 58.0 (45.0, 104.0) | .233 | .003 | .745 |

Abbreviations: AST, aspartate aminotransferase; CRP, C-reactive protein; Hb, hemoglobin; LDH, lactate dehydrogenase; PCT, procalcitonin; PLT, platelet count; WBC, white blood cell.

<sup>a</sup>Effect of group for each variable, the differences have been tested between standard group in three times (T0, T1, and T2) and canakinumab group at three times.

<sup>b</sup>Effect of time, for each variable, the differences have been tested between the means of the two groups at different time.

<sup>c</sup>Probability that the effects of time is greater in one distinct group (interaction time × group).
reactivity to other cytokines or other members of the IL-1 family.11 IL-1 is a proinflammatory cytokine capable of activating local and systemic inflammatory reactions. It can induce, acute phase plasma protein reactions with induction of the fever and bone and cartilage pain. Canakinumab, if used in juvenile idiopathic arthritis and other rare autoinflammatory conditions, such as Schnitzler syndrome, cryopyrin associated periodic syndrome and familial Mediterranean fever has been shown to improve symptoms and laboratory abnormalities.12,13 In fact this drug was approved for use in periodic fever syndromes in the United States in 2009.14 Canakinumab was also tested to block inflammation in cardiovascular diseases related to a subclinical inflammation, a condition associated with an increased risk of cardiovascular events.11,15

Several studies demonstrated that the cytokine storm, including IL1-β, TNF-α, IL-12 and IL-6 has a pivot role in the pathogenesis of severe acute respiratory syndrome associated to COVID-19.16 Moreover it has been widely demonstrated that in Middle East respiratory syndrome (MERS), a disease caused by another Coronavirus called MERS coronavirus, the cytokine gene expression of different ILs, including IL-1β, can be markedly high.17 Similar evidence suggests a similar pathogenesis in COVID-19, in fact inflammatory cytokines, such as IL1-β, are significantly elevated in patients with COVID-19.8

Accordingly, inflammatory cytokine cascade blockade is a promising therapy for COVID-19. There are some pilot studies on the use in COVID-19 of biological drugs, such us tocilizumab (17, 18), but there is no evidence yet on the possible role of canakinumab, which acts by inhibiting the cytokine cascade at an early step. We have recently published a pilot study on safety on canakinumab in patients with mild and severe COVID-19.18

In our cohort, canakinumab therapy has shown an improvement in blood chemistry parameters and in inflammation indices. This could be an important strategy to fight SARS-CoV-2 infection, whereas the elevated cytokine levels may be responsible of the tissue necrosis in the lung and, probably, of the lethal complications in COVID-19 patients.8 The decrease of d-dimer and fibrinogen after canakinumab administration could be useful in avoiding pulmonary vascular damage, responsible of the histological changes in COVID-19 patients. In addition, the block of the inflammatory cascade could avoid worsening patient's clinical condition. This hypothesis seems to be confirmed by the absence of worsening in the patients of our study, who instead quickly improved their pulmonary functions.

In fact, comparing patients treated with high Oxygen supports with VMK or NIV, we found that the patients in the canakinumab group, although more severely affected, reduced oxygen support quickly than the patients treated with standard therapy. Another confirmation of the patient improvement is the rapid reduction of lactate levels in patients in the canakinumab group, demonstrating the reduction of respiratory fatigue in these patients.

The present study has some limitations: it is a monocentric study, the comparator group includes patients with lower severity of COVID-19 and only non-intubated patients are enrolled. Finally, another important limitation is the small sample size.
5 CONCLUSION

In hospitalized adult patients with mild or severe non ICU COVID-19 requiring oxygen therapy, canakinumab could be a valid therapeutic option. Canakinumab therapy was associated with a rapid and long-lasting improvement in oxygenation levels without severe adverse events. Future randomized trials are necessary to confirm the efficacy of canakinumab in mild or severe COVID-19 patients with respiratory failure in a larger cohort.

CONFLICT OF INTERESTS
The authors declare that there are no conflict of interests.

AUTHOR CONTRIBUTIONS
Falasca Katia, Di Penta Myriam, and Claudio Ucciferri were responsible for the conception, design and write of this study. Marta Di Nicola and Michele Marchioni performed analysis and interpretation of all the data. Antonio Auricchio, Celletti Eleonora, and Sabatini Emanuela: data collection. Francesco Cipollone and Jacopo Vecchiet were revisioned the manuscript. All authors read and approved the final manuscript.

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID
Falasca Katia https://orcid.org/0000-0002-8795-5410
Claudio Ucciferri https://orcid.org/0000-0002-5866-3849
Antonio Auricchio https://orcid.org/0000-0003-3216-7895
Marta Di Nicola https://orcid.org/0000-0003-1748-1931
Michele Marchioni https://orcid.org/0000-0002-1702-4127
Francesco Cipollone https://orcid.org/0000-0002-5993-9341
Jacopo Vecchiet https://orcid.org/0000-0001-9250-4844

REFERENCES
1. Cheng VCC, Wong SC, Chen JHK, et al. Escalating infection control response to the rapidly evolving epidemiology of the coronavirus disease 2019 (COVID-19) due to SARS-CoV-2 in Hong Kong. Infect Control Hosp Epidemiol. 2020;41(5):493-498.
2. Helmy YA, Fawzy M, Elaswad A, Sobiei A, Kenney SP, Shehata AA. The COVID-19 pandemic: a comprehensive review of taxonomy, genetics, epidemiology, diagnosis, treatment, and control. J Clin Med. 2020;9(4):1225.
3. Balachandar V, Mahalaxmi I, Kaavya J, et al. COVID-19: emerging protective measures. Eur Rev Med Pharmacol Sci. 2020;24(6):3422-3425.
4. de Wit E, van Doremalen N, Falzarano D, Munster VJ. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol. 2016;14(8):523-534.
5. Brian DA, Baric RS. Coronavirus genome structure and replication. Curr Top Microbiol Immunol. 2005;287:1-30.
6. Barone Mirko UC, Cipollone Giuseppe. Murcelli felice recombiant human angiotensin-converting enzyme 2 and COVID-19 acute respiratory distress syndrome: a theoretical or a real resource? EJMO. 2020;4(2):139-140.
7. Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun. 2020;109:102433.
8. Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8(4):420-422.
9. Rondeau JM, Ramage P, Zurini M, Gram H. The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta. Mabs. 2015;7(6):1151-1160.
10. Goldstein H, Browne W, Rashash J. Multilevel modelling of medical data. Stat Med. 2002;21(2):2391-2351.
11. Abbate A, Toldo S, Marchetti C, Kron J, Van Tassell BW, Dinarello CA. Interleukin-1 and the inflammasome as therapeutic targets in cardiovascular disease. Circ Res. 2020;126(9):1260-1280.
12. Dinarello CA. The IL-1 family of cytokines and receptors in rheumatic diseases. Nat Rev Rheumatol. 2019;15(10):612-632.
13. Cavalli G, De Luca G, Campochiaro C, et al. Interleukin 1 receptor antagonist in a patient with resistant familial Mediterranean fever. J Autoimmun. 2012;51(6):1041.
14. Hong MD, Wang X, Poon L, et al. Respiratory failure in a larger cohort. Lancet Respir Med. 2020;8(4):420-422.
15. Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. Circulation. 2020;182:264-279.
16. Lau SKP, Lau CCY, Chan KH, et al. Delayed induction of proinflammatory cytokines in severe COVID-19 pneumonia. J Gen Virol. 2020;91(Pt 12):2679-2690.
17. Ucciferri CAA, Di Nicola M, Potere N, et al. Canakinumab in a subgroup of patients with COVID-19. Lancet. 2020;396:457-458.